PolyMedix Inc. (PYMX.OB) Presents New Data on Its Defensin-Mimetic Antibiotics at 52nd Annual ICAAC  
9/12/2012 10:04:03 AM

RADNOR, Pa., Sept. 11, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative approaches to transforming the treatment of infectious diseases, today announced that the Company presented data on its defensin-mimetic antimicrobial compounds at the 52nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The presentations included results of the first Phase 2 clinical study of PolyMedix's lead defensin-mimetic, brilacidin (PMX-30063), which showed high clinical response rates in patients with acute bacterial skin and skin structure infections (ABSSSI) caused by Staphylococcus aureus.